GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline posted a second-quarter earnings miss, but it announced a deal with the U.K. government for up to 60 million doses of the Covid-19 it is developing with partner Sanofi.

GlaxoSmithKline Stock Falls; Second-Quarter Earnings, Sales Miss Expectations

Glaxo misses both earnings and sales estimates in the second quarter of 2020. Stock down.

Glaxo (GSK) Misses Earnings & Revenue Estimates in Q2

Britain's GSK fell short of quarterly expectations for profit on Wednesday, as sales of the drugmaker's blockbuster shingles vaccine fell and stockpiling of pain and lung medication tapered as countries eased lockdowns.

GSK profit misses as Shingrix disappoints, stockpiling eases

Sanofi

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have reached an agreement with the United Kingdom to supply up to 60 million doses of their jointly-developed coronavirus vaccine, the two drugmakers announced Wednesday.

GlaxoSmithKline, Sanofi Ink Deal With UK To Supply Up To 60M Doses of COVID-19 Vaccine

Britain has signed a deal for the supply of up to 60 million doses of a potential coronavirus vaccine developed by Sanofi and GlaxoSmithKline.

UK signs deal for 60m doses of potential coronavirus vaccine

PHILADELPHIA, July 28, 2020 /PRNewswire/ -- GSK today announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2020-21 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug.

GSK begins shipping record number of its influenza vaccine doses for 2020-21 season for US market

Amgen

BioNTech SE

Dynavax Technologies

Gilead Sciences

Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.

Coronavirus Vaccine Development Puts These Stocks in Focus

AstraZeneca

Eli Lilly

Merck

Pfizer

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

U.S. drugmaker earnings heat up this week with spotlight on vaccine news

AbbVie

Takeda Pharmaceutical

They might not have the most hyped COVID-19 programs. But they do sport the juiciest dividends.

3 Coronavirus Stocks With the Highest Dividend Yields

It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus in all evaluated participants”. The project will now proceed to all-important phase 3 trials in Brazil and South Africa to test if it actually stops infection.

Covid-19 is Big Pharma’s chance to impress. But who’ll do best?

Novartis

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven second-quarter sales. Results will provide clarity on the impact of coronavirus on the company's business.

What's in the Cards for Glaxo (GSK) This Earnings Season?

Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.

Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease

These two pharma titans aren't equally appealing for investors, especially when considering their recent performance.

Better Buy: GlaxoSmithKline vs. Eli Lilly

It will own nearly 10% of the company and collaborate with it on the research and development of mRNA vaccine candidates.

GlaxoSmithKline Buys Stake in German Coronavirus Vaccine Developer CureVac

GlaxoSmithKline PLC (NYSE: GSK) is joining the race for a COVID-19 vaccine with its newest acquisition, but it may be tough to catch Pfizer and BioNTech after their most recent results.

GlaxoSmithKline Joins the Race for a COVID-19 Vaccine

GlaxoSmithKline (LON: GSK) said on Monday that it will invest £130 million in CureVac to get a 10% stake in the Tubingen-based biotechnology company. Shares of GSK were reported about 1.5% down in premarket trading on Monday and tanked another 1% on market open.

GlaxoSmithKline to get a 10% stake in CureVac for £130 million

GlaxoSmithKline plc (NYSE: GSK) is acquiring a 10% stake in German biopharmaceutical company CureVac, it announced Monday (London time).

GlaxoSmithKline To Acquire 10% Stake In Germany's CureVac, Collaborate On 5 mRNA Vaccines

Moderna

Novavax

Inovio Pharmaceuticals

Sinovac Biotech

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

Bed Bath & Beyond

Poseida Therapeutics

Akero Therapeutics Inc

Nkarta, Inc.

Perspecta Inc

Trinseo PLC

WESCO

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Bed Bath & Beyond, Poseida Therapeutics And More

DUBLIN--(BUSINESS WIRE)--The "Oral Care Market - Growth, Trends and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The global oral care market is projected to grow at a CAGR of 6.32% during the forecast period.

Insights into the Oral Care Global Industry to 2025 - Featuring GlaxoSmithKline, Sunstar Suisse & Lion Among Others - ResearchAndMarkets.com

Bristol-Myers

In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026.

Pharma Companies Look to Blockbusters to Drive Sales

Glaxo's (GSK) belantamab mafodotin gets FDA's Oncologic Drugs Advisory Committee votes as its benefits outweigh risks for relapsed/refractory multiple myeloma patients.

Glaxo's Multiple Myeloma Candidate Gets FDA Committee Nod

As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.

Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners

Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.

Glaxo Signs Another Deal to Develop a Coronavirus Vaccine

News for GlaxoSmithKline Stock (GSK)